The SFKs Lyn and Hck were found to be overexpressed in CML cell lines with BCR-ABL–independent imatinib resistance, and coinhibition of SFKs and BCR-ABL in these cells resulted in an enhanced apoptotic response [21,26]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.